Eucure Biopharma

Eucure Biopharma is a biotechnology company focused on the discovery and development of innovative immuno-oncology targeted antibodies. The company operates in the biopharmaceutical market, serving clients such as healthcare providers, research institutions, and pharmaceutical companies. Eucure's business model revolves around the research and development (R&D) of monoclonal antibodies, which are engineered to target specific cancer cells, enhancing the body's immune response against tumors. The company generates revenue through partnerships, licensing agreements, and the eventual commercialization of its antibody products. Eucure has a robust R&D pipeline with more than 10 targets, and several products have entered the Chemistry, Manufacturing, and Controls (CMC) stage, with clinical trials commencing in 2018. The company has also secured significant financing, including a Round B financing of RMB 120 million led by CMB International Capital and 3E Bioventure. This funding supports the advancement of its clinical pipeline, which includes multiple Investigational New Drug (IND) applications in the US. Keywords: immuno-oncology, targeted antibodies, monoclonal antibodies, clinical trials, R&D pipeline, biopharmaceutical, cancer treatment, CMC stage, IND applications, biotechnology.